Drug-induced decrease of serum alanine and aspartate aminotransferase activity in the rat, as a result of treatment with oxodipine, a new calcium channel blocker.
Chronic oral administration of oxodipine, a new calcium channel blocker, resulted in a reduction in the blood enzyme activity of alanine and aspartate aminotransferase. The reductions were both time and dose related. The decline in enzyme activities was accompanied by microscopic hepatic changes, which in the opinion of the authors should have been associated with an increase in the enzyme activities of alanine aminotransferase and aspartate aminotransferase. The effect was only partially reversed one month after the cessation of oxodipine treatment.
Waner
T
T
Life Science Research Israel, Nes Ziona, Israel.
Nyska
A
A
Bogin
E
E
Levy
R
R
Galiano
A
A
D000410:Alanine Transaminase / Q000097:blood*; D000818:Animals; D001219:Aspartate Aminotransferases / Q000097:blood*; D002121:Calcium Channel Blockers / Q000494:pharmacology* / Q000633:toxicity; D056486:Chemical and Drug Induced Liver Injury / Q000503:physiopathology; D003248:Constipation / Q000139:chemically induced / Q000503:physiopathology; D004095:Dihydropyridines / Q000494:pharmacology* / Q000633:toxicity; D004305:Dose-Response Relationship, Drug; D005260:Female; D008099:Liver / Q000033:anatomy & histology / Q000187:drug effects / Q000201:enzymology; D008297:Male; D051381:Rats; D011916:Rats, Inbred F344
D002121:Calcium Channel Blockers; D004095:Dihydropyridines; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase; C053783:oxodipine